Metabolomics Technology Applied to Non-Invasive Nash Biomarkers Research
News May 17, 2010
Metabolon, Inc. announces a study published in the Metabolism Journal released in the paper on April 28, 2010, by Satish C. Kalhan.
Metabolon studied plasma profiles from subjects with nonalcoholic fatty liver disease (NAFLD). Using Metabolon’s patented global metabolomic profiling platform, the study, authored by Satish C. Kalhan and his collaborators at the Cleveland Clinic and Case Western Reserve University School of Medicine and with scientists from Metabolon, identified a panel of potential noninvasive biomarkers in NAFLD and Nonalcoholic Steatohepatitis (NASH). The results represent both a significant step in understanding the disease and for the development of therapeutic interventions.
Researchers report that an experimental drug called vosoritide, allowed the average annual growth rate to increase in a study of 35 children and teenagers with a form of dwarfism. The average boost in height per year was ~6 centimeters (2.4 inches) which is close to growth rates among children of average stature.READ MORE